WASHINGTON, Dec. 22 -- Sen. Ruben Gallego issued the following press release:
In response to President Trump's recent announcement (https://senate.us14.list-manage.com/track/click?u=239475b0dda40486ab60cbc84&id=38e4da54c3&e=8a70c8b936) that nine drugmakers agreed to direct-to-consumer pricing through the TrumpRx drug purchasing platform, and the implementation of "Most Favored Nation" (MFN) pricing in Medicaid, Senator Ruben Gallego (D-AZ) called on the drug manufacturers to clarify the agreement and provide the public with details on the arrangement.
"It raises concern that to date, the public has been provided with only limited details, despite the significance of this arrangement for millions of patients, and that in return for this ar...